Financial Disclosures: Dr March has received
speaker fees from Pfizer, consulting fees from Pfizer and Wyeth, and research
support from Pfizer and Lilly, and has served as a scientific advisor for
Pfizer and on the data and safety monitoring board for Organon, Astra-Zeneca,
and Pfizer. Dr Rynn has served as a consultant and speaker for Pfizer and
as a consultant for Wyeth and Lilly.
Author Contributions: Dr March had full access
to all of the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analyses.
Study concept and design, obtained funding:
Acquisition of data: March, Foa, Gammon, Chrisman,
Curry, Fitzgerald, Sullivan, Franklin, Rynn, Zoellner, Leonard, Garcia, Freeman.
Analysis and interpretation of data: March,
Foa, Sullivan, Franklin, Huppert, Zhao.
Drafting of the manuscript: March, Foa, Sullivan,
Franklin, Zhao, Leonard.
Critical revision of the manuscript for important
intellectual content: March, Foa, Gammon, Chrisman, Curry, Fitzgerald,
Franklin, Huppert, Rynn, Zhao, Zoellner, Leonard, Garcia, Freeman.
Statistical analysis: March, Foa, Huppert,
Administrative, technical, or material support:
March, Foa, Gammon, Sullivan, Franklin, Rynn, Zhao, Zoellner, Leonard, Garcia,
Study supervision: March, Foa, Curry, Fitzgerald,
Franklin, Rynn, Leonard.
Funding/Support: The Pediatric OCD Treatment
Study was supported by NIMH grants 1 R01 MH55121 (Drs March and Foa) and 1
R01 MH55126 (Penn). Sertraline and matching placebo were provided to the POTS
under an independent educational grant from Pfizer Inc to Dr March.
Role of the Sponsors: Neither NIMH program
staff nor Pfizer Inc participated in the design and implementation of the
study, analysis of the data, or in authoring the manuscript.